Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 38,800 shares, an increase of 269.5% from the September 15th total of 10,500 shares. Based on an average daily volume of 139,900 shares, the short-interest ratio is presently 0.3 days.
Astellas Pharma Price Performance
Shares of Astellas Pharma stock traded down $0.07 on Thursday, reaching $11.65. The company’s stock had a trading volume of 144,424 shares, compared to its average volume of 248,163. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $21.08 billion, a P/E ratio of 166.43 and a beta of 0.37. The stock has a 50-day moving average price of $11.94 and a 200-day moving average price of $10.71. Astellas Pharma has a 52-week low of $9.15 and a 52-week high of $14.03.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.24 EPS for the quarter. The company had revenue of $3.03 billion during the quarter. Astellas Pharma had a net margin of 1.17% and a return on equity of 7.79%. Analysts expect that Astellas Pharma will post 0.54 EPS for the current year.
About Astellas Pharma
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
See Also
- Five stocks we like better than Astellas Pharma
- How to Plot Fibonacci Price Inflection Levels
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Which Wall Street Analysts are the Most Accurate?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- What is a Death Cross in Stocks?
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.